Etanercept en la enfermedad de injerto contra huésped aguda refractaria a corticoides

González Munguía, Silvia; Pérez León, Moisés; Piñero González, Marta; Díaz Pestano, Marina Magnolia; Molero Gómez, Rafael; Luzardo Henríquez, Hugo Daniel.
Farm. hosp ; 39(3): 147-151, mayo-jun. 2015. tab
Artículo en Español | IBECS (España) | ID: ibc-141566

Documentos relacionados

  1. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
  2. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract.
  3. [Etanercept on steroid-refractary acute graft-versus-host disease].
  4. Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
  5. ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.
  6. Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host disease.
  7. Tocilizumab as salvage treatment of refractory pulmonary acute graft-versus-host disease.
  8. Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease.
  9. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
  10. Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients.